Tango Therapeutics Inc
Ownership
Ownership Structure
Who owns Tango Therapeutics Inc (TNGX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 71.6% of the shares are freely tradable; institutional investors hold 113.9%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| RTW INVESTMENTS, LLC | 8.24 | 13,900,620 | +4.5 | 06/30/2026 |
| BlackRock Inc | 7.38 | 12,438,444 | +42.2 | 06/30/2026 |
| FMR Inc | 7.31 | 12,333,339 | +24.5 | 06/30/2026 |
| Farallon Capital Management, L.L.C. | 7.28 | 12,277,000 | +35.0 | 06/30/2026 |
| Boxer Capital Management, LLC | 6.45 | 10,876,219 | +0.0 | 06/30/2026 |
| The Goldman Sachs Group Inc | 5.92 | 9,980,620 | +96.6 | 06/30/2026 |
| TCG Crossover Management, LLC | 5.39 | 9,081,201 | -13.8 | 06/30/2026 |
| TRV GP IV, LLC | 3.78 | 6,374,574 | +0.0 | 06/30/2026 |
| Paradigm Biocapital Advisors LP | 3.77 | 6,357,523 | +58.6 | 06/30/2026 |
| T. Rowe Price Associates, Inc. | 3.77 | 6,348,827 | +613.8 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Crystal Adam | President, R&D | 115,743 | 2,685,238 $ | Oct 1, 2026 | direct |
| Newcomb Jessica | Principal Accounting Officer | 59,121 | 1,371,607 $ | Sep 22, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Crystal Adam | President, R&D | Sell | 600 | 25.32 | 15,192 |
| Oct 1, 2026 | Crystal Adam | President, R&D | Sell | 26,400 | 24.45 | 645,604 |
| Oct 1, 2026 | Crystal Adam | President, R&D | Other | 27,000 | 5.20 | 140,400 |
| Sep 22, 2026 | Newcomb Jessica | Principal Accounting Officer | Sell | 2,400 | 25.17 | 60,412 |
| Sep 22, 2026 | Newcomb Jessica | Principal Accounting Officer | Sell | 5,100 | 23.97 | 122,238 |
| Sep 22, 2026 | Newcomb Jessica | Principal Accounting Officer | Sell | 700 | 22.80 | 15,962 |
| Sep 1, 2026 | Crystal Adam | President, R&D | Sell | 27,000 | 22.37 | 603,909 |
| Sep 1, 2026 | Crystal Adam | President, R&D | Other | 27,000 | 5.20 | 140,400 |
| Aug 3, 2026 | Crystal Adam | President, R&D | Sell | 21,733 | 27.35 | 594,417 |
| Aug 3, 2026 | Crystal Adam | President, R&D | Sell | 5,267 | 26.79 | 141,100 |
| Aug 3, 2026 | Crystal Adam | President, R&D | Other | 27,000 | 5.20 | 140,400 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.